and an effective vaccine has been frustrated by HIV endless propensity to subvert the host defences and persist in small populations of long-lasting reservoirs despite antiretroviral therapy,
New knowledge should also help with using adenoviruses in vaccination and gene therapy e
#Scientists discover first NA ambulanceu of T researchers have discovered how severely damaged DNA is transported within a cell
and deliver drugs and vaccines, a olar spongethat can capture and release carbon dioxide emissions andplastic material that gets better with age.
#World's first malaria vaccine gets green light from European regulatory agency The world's first malaria vaccine has cleared its last major hurdle on its way to being approved for real-world use.
The European Medicines Agency (EMA) the regulatory group in the European union which roughly parallels the FDA gave a positive opinion of the vaccine,
The vaccine RTS S, also called Mosquirix, is the product of British pharmaceutical company Glaxosmithkline and is funded partly by the Bill and Melinda Gates Foundation.
It's not the only vaccine developed to fight malaria; an experimental malaria vaccine called Pfspz was found to be much more effective at preventing malaria infection.
Yet Mosquirix is the first to make it this far along in the approval process. Mosquirix helps to prevent infection from the Plasmodium falciparum, one of the deadlier malaria parasites.
The vaccine prompts the body to produce a higher amount of antibodies to stop the parasite from infecting the liver.
Early results of a clinical trial of Mosquirix showed that three doses of the vaccine could cut the risk of infection in half for children between between five and 17 months old.
and somewhat ineffective vaccine may outweigh the benefits. Still, Africa is need in desperate for a malaria vaccine,
even if it's only partially effective. Malaria infection spread through the blood by mosquito bites kills upwards of 500
"This vaccine could mean children will have only two bouts of malaria a year instead of five,"Dr. Martin De Smet,
#Ebola vaccine is 100 percent effective in Guinea trial, WHO reports A vaccine is"highly effective"against Ebola, according to the World health organization.
Early results from a trial in Guinea show that the drug protected 100 percent of the people who received it against Ebola.
the vaccine could help end the outbreak in West Africa.""The initial results are exciting and very promising,
and the hunt for a vaccine continues. Now, it seems that scientists have a real contender on their hands.
4, 000 people with close ties to Ebola patients either received the vaccine immediately or three weeks after the identification of an Ebola patient in their social circle.
no cases of Ebola were reported, starting 10 days after the initial vaccination, which is needed the time period to develop immunity.
There were 16 cases of Ebola in the group that were given the vaccine three weeks later, however."
Starting July 26th, all of the study's participants were given the vaccine immediately, instead of putting half in a delayed group.
These results don't mean that the world now has an Ebola vaccine. The vaccine needs to undergo further safety and efficacy testing.
The vaccine is also being tested on frontline health workers, Bertrand Draguez, medical director at Doctors Without Borders, said in a statement."
"These people have worked tirelessly and put their lives at risk every day to take care of sick people,
"If the vaccine is effective, then we are already protecting them from the virus. i
#HPV Vaccine Is Effective Against Multiple Cancer-Causing Strains The human papillomavirus vaccine, Cervarix, not only has the potential to prevent cervical cancer,
"The study confirms that targeting young adolescent girls before sexual debut for prophylactic HPV vaccination has a substantial impact on the incidence of high grade cervical abnormalities,"researcher Dan Apter,
They found that the vaccine was extremely effective in young women who had never been infected with HPV.
The women were followed for up to four years post-vaccination. The vaccine was distinctly more effective among ages 15-17 than ages18-25,
underscoring the value of vaccinating young adolescents, said Apter. The study is the final report from the Papilloma Trial Against Cancer in Young Adults (PATRICIA), a multinational clinical trial encompassing 14 countries in Europe, the Asia-Pacific region
The overall trial constituted the basis for approval of the Cervarix vaccine in Europe and the United states. While the trial did not investigate the vaccine's efficacy in males, sexually transmitted HPV causes anogenital and head and neck cancers in both males and females.
HPV-related head and neck cancers now number around 8, 400 in the United states, annually."
"The more adolescents are vaccinated, the closer we will be to eradicating high risk HPV viruses, "Apter said."
"So I think boys should also be vaccinated.""Cervical cancer is the fourth most common cancer among women.
The findings are detailed in the journal Clinical and Vaccine Immunology y
#Mastercard seeks to move digital money fast NEW YORK Mastercard wants to speed up digital payments. The financial services giant has launched just Mastercard Send,
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011